Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: OAD
Drug: Trazenta

First Posted Date: 2012-07-26

Last Posted Date: 2019-09-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 4876

Registration Number: NCT01650259

Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1005273 s.c. Placebo
Drug: BI 105273 i.v. Placebo
Drug: BI 1005273 i.v.
Drug: BI 1005273 s.c.

First Posted Date: 2012-07-26

Last Posted Date: 2014-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 88

Registration Number: NCT01650155

Locations: 🇩🇪
1294.1.1 Boehringer Ingelheim Investigational Site, Berlin, Germany

Afatinib Expanded Access Program

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2012-07-25

Last Posted Date: 2016-11-30

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT01649284

Locations: 🇺🇸
1200.45.004 Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States
🇺🇸
1200.45.116 Boehringer Ingelheim Investigational Site, Goodyear, Arizona, United States
🇺🇸
1200.45.078 Boehringer Ingelheim Investigational Site, Anaheim, California, United States

and more 63 locations

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: empagliflozin (low dose qd)
Drug: Placebo
Drug: empagliflozin (low dose bid)
Drug: Empagliflozin (high dose qd)
Drug: empagliflozin (high dose bid)

First Posted Date: 2012-07-25

Last Posted Date: 2015-07-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 983

Registration Number: NCT01649297

Locations: 🇺🇸
1276.10.11049 Boehringer Ingelheim Investigational Site, Jonesboro, Arkansas, United States
🇺🇸
1276.10.11033 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
🇺🇸
1276.10.11012 Boehringer Ingelheim Investigational Site, Norwalk, Connecticut, United States

and more 136 locations

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

Phase 1

Completed

Conditions: Breast Neoplasms
Stomach Neoplasms

Interventions: Drug: trastuzumab
Drug: Herceptin
Drug: afatinib

First Posted Date: 2012-07-25

Last Posted Date: 2017-12-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 13

Registration Number: NCT01649271

Locations: 🇫🇷
CTR Georges-François Leclerc, Dijon, France
🇫🇷
INS Claudius Regaud, Toulouse, France
🇫🇷
CTR René Gauducheau, Onco, St Herblain, Saint Herblain Cedex, France

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Dose escalation followed by treatment with MTD

First Posted Date: 2012-07-23

Last Posted Date: 2017-01-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 35

Registration Number: NCT01647711

Locations: 🇺🇸
Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States

Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2012-07-19

Last Posted Date: 2014-05-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1328

Registration Number: NCT01644734

Locations: 🇵🇱
Boehringer Ingelheim Investigational Site 44, Bialystok, Poland
🇵🇱
Boehringer Ingelheim Investigational Site 153, Chorzow, Poland
🇵🇱
Boehringer Ingelheim Investigational Site 88, Ciechanow, Poland

and more 244 locations

Single Rising Oral Doses of BI 1021958 in Healthy Chinese and Japanese Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Test drug
Drug: matching placebo

First Posted Date: 2012-07-12

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 80

Registration Number: NCT01638598

Locations: 🇰🇷
1310.3.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of

Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: BI 201335

First Posted Date: 2012-07-11

Last Posted Date: 2015-08-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 34

Registration Number: NCT01637922

Locations: 🇺🇸
1220.57.0001 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
🇺🇸
1220.57.0003 Boehringer Ingelheim Investigational Site, Salt Lake City, Utah, United States
🇺🇸
1220.57.0002 Boehringer Ingelheim Investigational Site, Overland Park, Kansas, United States

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: Tiotropium low dose mcg
Drug: Tiotropium high dose

First Posted Date: 2012-07-06

Last Posted Date: 2016-01-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 401

Registration Number: NCT01634152

Locations: 🇺🇸
205.446.01009 Boehringer Ingelheim Investigational Site, Columbia, Missouri, United States
🇺🇸
205.446.01012 Boehringer Ingelheim Investigational Site, Arlington, Texas, United States
🇨🇦
205.446.02001 Boehringer Ingelheim Investigational Site, Sherbrooke, Quebec, Canada

and more 91 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy